Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Phase 1/2 Completed 276 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupSingle-blindTreatment

Summary

This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.

Timeline

Start: 2009-01
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Latanoprost	Small molecule	0.005 %	—
Subject	RKI983A	Unknown	0.05 %	Other
Subject	RKI983A	Unknown	0.1 %	Other

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

Summary

Timeline

Drugs

Indications